Theragen Etex said Tuesday that the company and its subsidiaries recorded combined sales of 37 billion won ($30.4 million) in the second quarter of this year, a 44.9 percent increase from the same period in 2018.
The company also registered 2 billion won in operating profit, turning to a surplus from a deficit from the same period of last year, and posted a net profit of 5 billion won, a drastic 543.6 percent increase compared to the previous year.
Aside from its subsidiaries, Theragen Etex alone posted 18.1 billion won in sales, 1.4 billion in operating profit and 710 million won in net profit.
"The prominent increase in revenue is the result of the company actively seeking to increase sales and reduce costs in all business areas, including pharmaceuticals, drug distribution, and genomes," a company official said. "Also, earnings improved thanks to increased bio orders and improved cost structure."
The company will do its best to continue the growth in the second-half year, he added.
<© Korea Biomedical Review, All rights reserved.>